China Healthcare Reporter

Bloomberg News is one of the biggest financial and business news organizations in the world. We lead the way in breaking news and providing analysis on financial markets, from daily coverage through to in-depth features. We are known for our quality, accuracy and ability to deliver news investors can use. It's what keeps us inventing and re-inventing, all the time.

After three years of Covid-19 pandemic, China's healthcare sector is at a crossroad. While policymakers and biotech executives are brooding over the setbacks in mastering mRNA technology that define the future of vaccine-making, drug developers in China are still seeking to break into western markets by nabbing US and Europe approval for homegrown medicines. Meanwhile, a population crisis is quietly brewing, with the number of people in China dropping for the first time in six decades amid declining fertility rates and a rapidly aging society, posing challenges around everything from economic vitality to supporting the swelling ranks of geriatrics in the world's second-largest economy.

We are looking for a reporter who's willing to delve deep into the world of Chinese biotech and track companies' rise and fall in the global race to deliver first-in-class medicines for patients both in China and the rest of the world. The reporter should remain eagle-eyed on deals struck between Chinese drugmakers and western big pharmaceutical companies to chronicle the rise of China not just as the world's second-biggest market for pharmaceutical products but also as a source of medical innovation, or the lack thereof. You should also spot news related to China's population challenges, ranging from government policies to encouraging couples to have more babies and supporting elders.